Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Divis Laboratories Ltd Performance

Today's Low
3,686.20
arrowIcon
Today's High
3,781.00
52 Wk Low
3,051.00
arrowIcon
52 Wk High
4,074.40


Open

3699.95

Traded Value (Cr)

119.95 Cr

Prev. Close

3716.55

VWAP

3742.71

Volume

4,28,141

Face Value

2

Divis Laboratories Ltd Fundamentals

Market Cap
₹ 1,00,940 Cr
P/E Ratio (TTM)
72.98
P/B Ratio
7.96
Debt to Equity
0.00
ROE
10.50 %
EPS (TTM)
52.10
Dividend Yield
0.79%
Book Value
477.54

Click here to know more about Fundamentals

Divis Laboratories Ltd F&O

Divis Laboratories Ltd Option Chain

Divis Laboratories Ltd Financials

Divis Laboratories Ltd Financials

Divis Laboratories Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 51.92 % 51.92 % 51.93 % 51.93 %
FII 14.68 % 14.86 % 14.60 % 14.70 %
Mutual Funds 14.28 % 13.72 % 13.62 % 13.20 %
Others 10.43 % 10.64 % 10.84 % 10.90 %
Retail 8.69 % 8.85 % 9.02 % 9.28 %

Promoters

51.92%

FII

14.68%

Mutual Funds

14.28%

Others

10.43%

Retail

8.69%

Promoters

51.92%

FII

14.86%

Mutual Funds

13.72%

Others

10.64%

Retail

8.85%

Promoters

51.93%

FII

14.60%

Mutual Funds

13.62%

Others

10.84%

Retail

9.02%

Promoters

51.93%

FII

14.70%

Mutual Funds

13.20%

Others

10.90%

Retail

9.28%

Resistance and Support

₹3,724.25

PIVOT

resistance-arrow
Resistance
First Resistance₹3,762.300
Second Resistance₹3,808.050
Third Resistance₹3,846.100
support-arrow
Support
First Resistance₹3,678.500
Second Resistance₹3,640.450
Third Resistance₹3,594.700
RSI73.174
MACD164.191
ADX25.654
CCI72.575

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day428,141136,27842.76
Week583,837290,47165.44
1 Month573,810345,54061.06
6 Months428,141428,141100.00

About Divis Laboratories Ltd

Divis Laboratories Ltd holds a prominent position in the Indian pharmaceutical industry, focusing on researching, developing, and producing a diverse array of Active Pharmaceutical Ingredients (APIs) and Intermediates. The company's state-of-the-art manufacturing facilities comply with global regulatory standards, including the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA) approvals.

Divis Laboratories' product portfolio covers a diverse range of therapeutic areas, catering to various healthcare needs. Their products find applications in areas such as cardiovascular, anti-infective, central nervous system, anti-inflammatory, and many others. The company places a strong emphasis on research and development, continuously striving to innovate and develop new molecules and processes. This commitment to R&D has enabled them to stay at the forefront of the pharmaceutical industry and provide cutting-edge solutions to global healthcare challenges.

Company Establishment

Divis Laboratories Ltd was established in 1990 in Hyderabad, India. Since its inception, the company has grown to become a prominent player in the pharmaceutical industry. With a focus on research, development, and manufacturing of Active Pharmaceutical Ingredients (APIs) and Intermediates, Divis Laboratories has earned a reputation for delivering high-quality products and services both in the domestic and international markets.

The company's commitment to innovation, compliance with global regulatory standards, and diverse product portfolio have contributed to its consistent growth and success over the years. Divis Laboratories continues to expand its presence in the pharmaceutical market, solidifying its position as a leading Indian pharmaceutical company.

Divis Laboratories Ltd Total Stocks & IPO Raise Out

Divis Laboratories Ltd was actively traded on the stock market. It is listed on various stock exchanges in India, such as the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). Being a prominent player in the pharmaceutical industry, Divis Laboratories has garnered significant investor interest and has become a well-established company in the Indian stock market. 

Divis Laboratories Ltd had gone public through an initial public offering (IPO) in March 2003. The specific issue date for the IPO was March 19, 2003. During the IPO, Divis Laboratories offered its shares to the public for the first time, allowing investors to purchase the company's stock. The IPO was a significant milestone in the company's journey as it transitioned from a privately held entity to a publicly traded company on the stock exchanges. In recent times the share price of Divi's Laboratories Ltd has been experiencing positive momentum, reflecting the company's strong performance and investor confidence in its pharmaceutical products and services.

About The Company

Divis Laboratories operates with a commitment to quality and compliance. Its manufacturing facilities adhere to stringent international standards, including certifications from regulatory bodies such as the United States Food and Drug Administration (US FDA), the European Medicines Agency (EMA), and other international agencies. These certifications testify to the company's adherence to global best practices, ensuring the safety, efficacy, and consistency of its products.

The company's diversified product portfolio covers a wide range of therapeutic areas, including cardiovascular, central nervous system, anti-infective, oncology, and more. Its products find application in various medical treatments, catering to diverse healthcare needs across the globe.

Divis Laboratories Ltd group of companies

Divis Laboratories Ltd is the flagship company of the Divis Group, which is a conglomerate of companies with diverse business interests.

Divis Laboratories Ltd: Divis Laboratories Ltd serves as the primary pharmaceutical firm involved in the exploration, advancement, and production of Active Pharmaceutical Ingredients (APIs) and Intermediates.

Divi's Nutraceuticals: A division of Divis Laboratories focused on the development and manufacturing of nutraceutical products, including vitamins, minerals, and dietary supplements.

Divi's Laboratories USA Inc: This subsidiary is based in the United States and handles sales, marketing, and customer support for the company's products in North America.

Divis Labs SRL: A subsidiary in Europe, Divis Labs SRL manages the company's European operations and serves as a hub for sales and distribution across the region.

Divis Laboratories Japan K.K.: Another subsidiary, this entity handles sales and distribution in Japan, strengthening the company's presence in the Asian market.

Divis Laboratories (Shanghai) Co. Ltd. : This subsidiary is located in China and plays a vital role in the company's operations and expansion in the Chinese market.

Divis Laboratories Ltd Share Price Today

The stock prices of individual companies are influenced by various factors, resulting in continuous fluctuations and creating a dynamic trading environment throughout the day. Factors such as company performance, market sentiment, economic conditions, industry trends, and global events can impact the share price of a company on the stock market. You can find the Divis Laboratories Ltd share price, from the above section.

Managing Director

Murali K Divi

Founded

1990

NSE Symbol

DIVISLAB

Divis Laboratories Ltd Management

NameDesignation
Murali K DiviChairman & Managing Director
N V RamanaExecutive Director
Madhusudana Rao DiviWhole Time Director (Projects)
Kiran S DiviWhole Time Director & CEO
G Suresh KumarIndependent Director
Ranga Rao RavipatiIndependent Director
K V K SeshavataramIndependent Director
Ramesh B V NimmagaddaChairman(Non Exe)&Director(Ind
Nilima MotapartiWhole Time Director -Commercia
S GanapatyIndependent Director
Sunaina SinghIndependent Director
Kosaraju Veerayya ChowdaryIndependent Director
Satish ChoudhuryCompany Sec. & Compli. Officer

Divis Laboratories Ltd News

Divis Laboratories Ltd soars 1.13%, up for fifth straight session
Divis Laboratories Ltd is quoting at Rs 3726.65, up 1.13% on the day as on 12:44 IST on the NSE. The stock is up 28.96% in last one year as compared to a 27.97% spurt in NIFTY and a 56.75% spurt in the Nifty Pharma.
Divis Laboratories Ltd soars 1.51%, up for third straight session
Divis Laboratories Ltd is quoting at Rs 3622, up 1.51% on the day as on 12:49 IST on the NSE. The stock is up 26% in last one year as compared to a 28.88% gain in NIFTY and a 58.71% gain in the Nifty Pharma index.
Divis Laboratories Ltd soars 0.23%, up for fifth straight session
Divis Laboratories Ltd is quoting at Rs 3613.2, up 0.23% on the day as on 12:44 IST on the NSE. The stock is up 30.58% in last one year as compared to a 30.46% spurt in NIFTY and a 63.86% spurt in the Nifty Pharma.
Divis Laboratories Ltd gains for third consecutive session
Divis Laboratories Ltd is quoting at Rs 3590.05, up 1.28% on the day as on 12:49 IST on the NSE. The stock is up 26.66% in last one year as compared to a 26.72% jump in NIFTY and a 63.77% jump in the Nifty Pharma index.
Divis Laboratories Ltd down for fifth straight session
Divis Laboratories Ltd is quoting at Rs 3488.35, down 0.01% on the day as on 13:19 IST on the NSE. The stock jumped 21.92% in last one year as compared to a 28.68% rally in NIFTY and a 60.99% spurt in the Nifty Pharma index.
Divi's Labs posts PAT of Rs 358 crore in Q3; material consumption at 39% of sales
Divi's Laboratories' consolidated net profit for Q3 FY24 was Rs 358 crores as against a PAT of Rs 306 crore for Q3 FY23, thereby recording a growth of 17% YoY.
Divis Laboratories appoints director
With effect from 10 February 2024
Divi's Laboratories consolidated net profit rises 16.99% in the December 2023 quarter
Sales rise 8.61% to Rs 1855.00 crore
Divis Laboratories to discuss results
On 10 February 2024
Divis Laboratories Ltd eases for fifth straight session
Divis Laboratories Ltd is quoting at Rs 3682.7, down 0.3% on the day as on 13:19 IST on the NSE. The stock jumped 8.77% in last one year as compared to a 19.49% rally in NIFTY and a 36.07% spurt in the Nifty Pharma index.

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,68,909 Cr
₹ 1,537.55
(-0.16 %)
89.51
CIPLA₹ 1,11,029 Cr
₹ 1,375.20
(-0.45 %)
33.78
DRREDDY₹ 1,00,930 Cr
₹ 6,050.35
(0.66 %)
25.37
ZYDUSLIFE₹ 95,074 Cr
₹ 944.85
(1.04 %)
35.39
MANKIND₹ 91,376 Cr
₹ 2,281.05
(0.60 %)
55.39

Divis Laboratories Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Divis Laboratories Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Divis Laboratories Ltd's share price is ₹3,764.20 as of April 16, 2024

Divis Laboratories Ltd's P/E ratio is 72.98 times as of April 16, 2024.

Divis Laboratories Ltd's most recent financial reports indicate a price-to-book ratio of 7.96, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Divis Laboratories Ltd's market is 100,940 Cr as on April 16, 2024.

The current financial records of Divis Laboratories Ltd show a 10.50% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Divis Laboratories Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Divis Laboratories Ltd's 52-week high and low as of April 16, 2024 are ₹3781 and ₹3686.2 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Divis Laboratories Ltd stands at 51.92%. During the same period, Institutional Investors have shown a slight decrease in their holdings, dropping from 14.86% to 14.68%.